Fly News Breaks for November 5, 2019
TNDM
Nov 5, 2019 | 08:53 EDT
Lake Street analyst Brooks O'Neil views the selloff today in Tandem Diabetes Care as a buying opportunity. The analyst views the Q3 earnings report as "solid" and thinks Q4 is now "derisked." He affirms a Buy rating on the shares with a $100 price target.
News For TNDM From the Last 2 Days
TNDM
Apr 25, 2024 | 06:02 EDT
Leerink upgraded Tandem Diabetes to Outperform from Market Perform with a $45 price target.